PURPOSE: Phosphorothioate antisense oligodeoxynucleotides are promising therapeutic candidates. When given systemically in clinical trials they are administered via slow intravenous infusion to avoid their putative plasma concentration-dependent haemodynamic side-effects. In this study, we have evaluated alternative parenteral and non-parenteral administration routes which have the potential to enhance the therapeutic and commercial potential of these agents. METHODS: The delivery of CGP 64128A by intravenous, subcutaneous, intra-peritoneal, oral and intra-tracheal (pulmonary) routes was investigated in rats using radiolabelled compound and supported by more specific capillary gel electrophoretic analyses. RESULTS: Intravenously administered CGP 64128A exhibited the rapid blood clearance and distinctive tissue distribution which are typical for phosphorothioate oligodeoxynucleotides. Subcutaneous and intraperitoneal administration resulted in significant bioavailabilities (30.9% and 28.1% over 360 min, respectively) and reduced peak plasma levels when compared with intravenous dosing. Administration via the gastrointestinal tract gave negligible bioavailability (< 2%). Intra-tracheal administration resulted in significant but dose-dependent bioavailabilities of 3.2, 16.5 and 39.8% at 0.06, 0.6 and 6.0 mg/kg, respectively. CONCLUSIONS: Significant bioavailabilities of CGP 64128A were achieved following subcutaneous, intra-peritoneal and intra-tracheal administration. Pulmonary delivery represents a promising mode of non-parenteral dosing for antisense oligonucleotides. The dose-dependent increase in pulmonary bioavailability suggests that low doses may be retained in the lungs for local effects whereas higher doses may be suitable for the treatment of a broader spectrum of systemic diseases.
PURPOSE:Phosphorothioate antisense oligodeoxynucleotides are promising therapeutic candidates. When given systemically in clinical trials they are administered via slow intravenous infusion to avoid their putative plasma concentration-dependent haemodynamic side-effects. In this study, we have evaluated alternative parenteral and non-parenteral administration routes which have the potential to enhance the therapeutic and commercial potential of these agents. METHODS: The delivery of CGP 64128A by intravenous, subcutaneous, intra-peritoneal, oral and intra-tracheal (pulmonary) routes was investigated in rats using radiolabelled compound and supported by more specific capillary gel electrophoretic analyses. RESULTS: Intravenously administered CGP 64128A exhibited the rapid blood clearance and distinctive tissue distribution which are typical for phosphorothioate oligodeoxynucleotides. Subcutaneous and intraperitoneal administration resulted in significant bioavailabilities (30.9% and 28.1% over 360 min, respectively) and reduced peak plasma levels when compared with intravenous dosing. Administration via the gastrointestinal tract gave negligible bioavailability (< 2%). Intra-tracheal administration resulted in significant but dose-dependent bioavailabilities of 3.2, 16.5 and 39.8% at 0.06, 0.6 and 6.0 mg/kg, respectively. CONCLUSIONS: Significant bioavailabilities of CGP 64128A were achieved following subcutaneous, intra-peritoneal and intra-tracheal administration. Pulmonary delivery represents a promising mode of non-parenteral dosing for antisense oligonucleotides. The dose-dependent increase in pulmonary bioavailability suggests that low doses may be retained in the lungs for local effects whereas higher doses may be suitable for the treatment of a broader spectrum of systemic diseases.
Authors: B P Monia; H Sasmor; J F Johnston; S M Freier; E A Lesnik; M Muller; T Geiger; K H Altmann; H Moser; D Fabbro Journal: Proc Natl Acad Sci U S A Date: 1996-12-24 Impact factor: 11.205
Authors: N Dean; R McKay; L Miraglia; R Howard; S Cooper; J Giddings; P Nicklin; L Meister; R Ziel; T Geiger; M Muller; D Fabbro Journal: Cancer Res Date: 1996-08-01 Impact factor: 12.701
Authors: P A Cossum; H Sasmor; D Dellinger; L Truong; L Cummins; S R Owens; P M Markham; J P Shea; S Crooke Journal: J Pharmacol Exp Ther Date: 1993-12 Impact factor: 4.030
Authors: Sterghios A Moschos; Manfred Frick; Bruce Taylor; Paul Turnpenny; Helen Graves; Karen G Spink; Kevin Brady; David Lamb; David Collins; Thomas D Rockel; Markus Weber; Ovadia Lazari; Luis Perez-Tosar; Sally A Fancy; Chris Lapthorn; Martin X Green; Steve Evans; Matthew Selby; Gareth Jones; Lyn Jones; Sarah Kearney; Houria Mechiche; Diana Gikunju; Romesh Subramanian; Eugen Uhlmann; Marion Jurk; Jörg Vollmer; Giuseppe Ciaramella; Michael Yeadon Journal: Mol Ther Date: 2011-10-04 Impact factor: 11.454
Authors: Michael M Swarbrick; Peter J Havel; Arthur A Levin; Andrew A Bremer; Kimber L Stanhope; Madeline Butler; Sheri L Booten; James L Graham; Robert A McKay; Susan F Murray; Lynnetta M Watts; Brett P Monia; Sanjay Bhanot Journal: Endocrinology Date: 2009-01-22 Impact factor: 4.736